UNSPSC 51373202: Tapentadol

This classification denotes an analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H8A007M585. European Medicines Agency schedules Tapentadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31821. Tapentadol generally arises in the molecular formula C14H23NO. The term TAPENTADOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule tapentadol under HS 29222900 and SITC 51462.

As of Q4 2014, TAPENTADOL remains the US FDA Preferred Term for this commodity. Tapentadol bears US NLM identifiers UMLS ID C2001271 and NCI Concept Code C72139. SMILES: C1=CC=C(C=C1)SCC(CC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)O.

UNSPSC 51373202 Tapentadol is a Commodity code representing individual pharmaceutical products procured by state and local health and social-service agencies. Recent solicitations under this code show state and local governments buying naloxone and related harm-reduction medications, generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances representing multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Procurement mechanisms span competitive sealed bids for smaller annual purchases, RFPs for cooperative contracts serving dozens of participating entities, and exploratory RFIs gathering vendor capability and market intelligence before formal competitive solicitations.

Recent activity concentrates in Florida, Texas, Minnesota, and Oregon, with the most substantial opportunity being MMCAP's generic pharmaceutical contract covering multiple states through authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson. The Minnesota Department of Administration issued the MMCAP RFP (S1070000015802) with a March 26, 2026 response deadline, seeking manufacturers to supply generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with evaluations weighted 75 percent on price competitiveness and 10 percent on fixed pricing for the contract term; vendors must maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, funded potentially through FEMA and requiring E-Verify compliance and workers' compensation insurance. The Texas HHS Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed as preliminary market intelligence before a formal RFP.